Clevudine - CAS 163252-36-6
Catalog number:
163252-36-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C10H13FN2O5
Molecular Weight:
260.22
COA:
Inquire
Targets:
HBV
Description:
Clevudine is metabolized in cells by the cellular thymidine kinase as well as deoxycytidine kinase to its monophosphate, and subsequently to the di- and triphosphate.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B.
Shim JJ1, Kim JW, Lee CK, Jang JY, Kim BH. J Gastroenterol Hepatol. 2014 Sep;29(9):1699-705. doi: 10.1111/jgh.12612.
BACKGROUND AND AIMS: Analysis of alpha-fetoprotein (AFP) levels affords limited diagnostic accuracy because of the high false-positive rates, especially in those with active chronic hepatitis B (CHB). We measured AFP levels before and after commencement of oral antiviral therapy and explored the utility of these data in terms of early detection of hepatocellular carcinoma (HCC) in patients with CHB.
2.A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hep
Tak WY1, Yang JM2, Kim BI3, Baik SK4, Cheon GJ5, Byun KS6, Kim do Y7, Yoo BC8. Hepatol Int. 2014 May 25;8(3):375-81. doi: 10.1007/s12072-014-9537-5. eCollection 2014.
PURPOSE: Clevudine 30 mg showed potent antiviral activity with a marked post-treatment antiviral effect. However, long-term treatment with clevudine monotherapy induced resistance and myopathy in some cases. The objective of this study is to evaluate the preliminary efficacy and safety of the combination of clevudine 20 mg and adefovir compared to clevudine monotherapy.
3.Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.
Shin JH1, Kwon HJ, Jang HR, Lee JE, Gwak GY, Huh W, Jung SH, Lee JH, Kim YG, Kim DJ, Oh HY. Medicine (Baltimore). 2016 Jan;95(1):e2400. doi: 10.1097/MD.0000000000002400.
Renal functional decline that is frequently seen during chronic hepatitis B (CHB) treatment can exert adverse effects on overall prognosis. It, however, is difficult to distinguish vulnerable patients who may experience renal dysfunction because most previous CHB studies were conducted in relatively healthy individuals. In this retrospective observational study, renal functional decline in CHB patients receiving oral antiviral agents for more than 6 months was analyzed and risk factors of chronic kidney disease (CKD) progression were determined.Renal functional decline was defined when the estimated glomerular filtration rate (eGFR) decreased by more than 25% from baseline and rapid CKD progression was defined as eGFR decreased by more than 5 mL/min/1.73 m/y among patients who experienced renal functional decline.A total of 4178 patients were followed up for a median 23 months. Antiviral agents included lamivudine (17.0%), adefovir (3.7%), entecavir (70.
4.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY1, Paik YH1, Sohn W1, Cho HC2, Gwak GY1, Choi MS1, Lee JH1, Koh KC1, Paik SW1, Yoo BC1. Gut. 2014 Dec;63(12):1943-50. doi: 10.1136/gutjnl-2013-306409. Epub 2014 Mar 10.
BACKGROUND: It is generally stated that oral antiviral therapy in patients with chronic hepatitis B (CHB) decreases the risk of developing hepatocellular carcinoma (HCC). Although oral nucleos(t)ide analogues (NUCs) may induce a state similar to inactive stage CHB, the long-term risk for HCC in patients treated with NUCs compared with inactive CHB is unclear.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HBV Products


AB-423

AB-423 is a small-molecule inhibitor of HBV core protein used to treat chronic HBV infection. In preclinical study, AB-423 was indicated to damage assembly of t...

CAS 163252-36-6 Clevudine

Clevudine
(CAS: 163252-36-6)

Clevudine is metabolized in cells by the cellular thymidine kinase as well as deoxycytidine kinase to its monophosphate, and subsequently to the di- and triphos...

CAS 209216-23-9 Entecavir Hydrate

Entecavir Hydrate
(CAS: 209216-23-9)

Entecavir-triphosphate is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than lamivudine-triphosphate against 3TC-resistant ...

CAS 118159-48-1 Bicyclol

Bicyclol
(CAS: 118159-48-1)

Bicyclol is a anti-hepatitis drug, used in China for chronic hepatitis B and presumably C.

ABI-H-0731

ABI-H-0731 is one of a class of novel and oral CpAMs developed for the potential use to treat chronic hepatitis B virus infection and disorders associated with ...

CAS 476617-51-3 Bay 41-4109 less active enantiomer

Bay 41-4109 less active enantiomer
(CAS: 476617-51-3)

Bay 41-4109 less active enantiomer exhibits less activity than Bay 41-4109 that is a novel class of drugs and inhibits hepatitis B virus (HBV) capsid formation ...

CAS 142217-69-4 Entecavir

Entecavir
(CAS: 142217-69-4)

An oral antiviral drug used in the treatment of hepatitis B infection. A guanine analogue that inhhibits all three steps in the viral replication process.

CAS 840529-13-7 Helioxanthin 8-1

Helioxanthin 8-1
(CAS: 840529-13-7)

Helioxanthin 8-1 is an analogue of helioxanthin, which exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity. It showed the most potent antiHBV activi...

CAS 142340-99-6 Adefovir Dipivoxil

Adefovir Dipivoxil
(CAS: 142340-99-6)

Adefovir Dipivoxil is a reverse transcriptase inhibitor, used in the treatment of chronic hepatitis B virus (HBV).

CAS 198821-22-6 Merimepodib

Merimepodib
(CAS: 198821-22-6)

Merimepodib is orally bioavailable IMPDH inhibitor.

CAS 203935-39-1 Helioxanthin derivative 5-4-2

Helioxanthin derivative 5-4-2
(CAS: 203935-39-1)

Helioxanthin derivative 5-4-2 had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 microM, respectively. The lamivudine-resistant HB...

CAS 18920-47-3 Helioxanthin

Helioxanthin
(CAS: 18920-47-3)

Helioxanthin and its analogues decreased cellular RNA levels of HBV and antigen expression as well as selective inhibition of HBV replication in a cell culture ...

CAS 92562-88-4 Lagociclovir

Lagociclovir
(CAS: 92562-88-4)

Lagociclovir is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV.

CAS 3424-98-4 Telbivudine

Telbivudine
(CAS: 3424-98-4)

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names S...

Chemical Structure

CAS 163252-36-6 Clevudine

Quick Inquiry

Verification code

Featured Items